scout
Commentary|Videos|December 13, 2024

Dr Rozenblit on Pembrolizumab Outcomes by TMB Status in HR+ Metastatic Breast Cancer

Fact checked by: Ashling Wahner , Chris Ryan

Mariya Rozenblit, MD, discusses how genomic alterations and TMB influence the efficacy of immune checkpoint inhibitors in HR+ metastatic breast cancer.

Mariya Rozenblit, MD, assistant professor, medicine (medical oncology), Yale School of Medicine, discusses findings from a study evaluating the prevalence of actionable genomic alterations and the predictive value of tumor mutational burden (TMB) for the efficacy of immune checkpoint inhibitors in patients with hormone receptor (HR)–positive, HER2-negative metastatic breast cancer.

Newsletter

Stay up to date on the most recent and practice-changing oncology data


Latest CME